Paloma-3
03 Jan 2023
Trial Summary
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration.
Acronym:
PALOMA-3
ACTRN/NCT /ethics:
NCT05388669
Scientific title:
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Sponsor / Cooperative group:
Janssen Research & Development, LLC
Trial & Patient Characteristics
| Cancer Type | Non-small Cell Lung Cancer |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2022-08-05 |
| Anticipated End Date | 2024-08-01 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead/Kate Penda |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Dr Rohit Joshi |
| Recruitment Status | Recruiting |